Comparing Mavenclad vs Mayzent
| Mavenclad (cladribine) | Mayzent (siponimod) |
|
|---|
| Mavenclad (cladribine) | Mayzent (siponimod) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Mavenclad is used to treat relapsing forms of MS, to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile it is usually reserved for... View more |
Prescription only
Mayzent is an S1P receptor modulator that may be used to treat relapsing forms of multiple sclerosis in adults. It is only suitable for people with a certain CYP2C9 genetic type and genotype testing... View more |
Related suggestions Popular comparisons
|
|||||||||||||||
| More about Mavenclad (cladribine) | More about Mayzent (siponimod) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Mavenclad has an average rating of 8.8 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
Mayzent has an average rating of 6.8 out of 10 from a total of 13 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Mavenclad side effects |
View all Mayzent side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Mavenclad prices |
View all Mayzent prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other cladribine brands include: Cladribine Novaplus |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
6.7 hours |
30 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 507 drugs are known to interact with Mavenclad:
|
A total of 757 drugs are known to interact with Mayzent:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
March 29, 2019 |
March 26, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.